Live
CellPan-neurodegeneration proteomics reveals disease subtypes and molecular signaturesFierceBiotechMedtronic, Biotronik heart hardware make strides in conduction system pacingFierceBiotechGE HealthCare claims photon-counting CT clearance from FDACytiva (Google News)Cytiva-SR-TIGET Joint Venture Addresses Gene Therapy Bottlenecks - Inside Precision MedicineBioPharma DiveRA Capital targets China with latest SPAC dealIlluminaIllumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWSWatersWaters Corporation stock refinances $3.5 billion debt with senior notes offering amid stable analyst - AD HOC NEWSCytiva (Google News)Cytiva and Yoshindo advance domestic biosimilar manufacturing in Japan - BioSpectrum AsiaFierceBiotechShionogi pays Apnimed $100M for joint venture to awaken sleep disorder dreamFierceBiotechOcugen eye disease gene therapy hits ph. 2 targets but underwhelms investorsBioWorldAustralia’s R&D reset puts biotech translation in focusBioWorldSimcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer
BioWorld Mar 24, 2026

Australia’s R&D reset puts biotech translation in focus

Australia’s R&D reset puts biotech translation in focus

Original
Body unavailable. Use the original source.

Directory

59 All